ArticlePharmacoEconomics2016

The Cost Effectiveness of Docetaxel and Active Symptom Control versus Active Symptom Control Alone for Refractory Oesophagogastric Adenocarcinoma: Economic Analysis of the COUGAR-02 Trial.

David M Meads et al.PubMed ↗Publisher ↗

No numbers read from the abstract.